Testing LHP588 for Alzheimer's linked to a mouth bacteria
Part of Brain & nervous system, Mental health clinical trials.
This trial tests a new medication, LHP588, for people with Alzheimer's who also have a common mouth bacteria called P. gingivalis. The goal is to see if targeting this bacteria can help slow down memory loss.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with Alzheimer's disease (mild or moderate stage).
- A special test shows you have a type of bacteria called P. gingivalis in your saliva.
- A blood test shows higher levels of a brain protein called pTau217, which is linked to Alzheimer's.
- Your Alzheimer's medications (if any) must be the same dose for at least 3 months before starting and stay the same during the trial.
- You cannot have had cancer treatment in the last 5 years, serious heart problems, or other major unstable medical conditions.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies whether treating periodontal (gum) disease can help people who have probable Alzheimer’s disease. You may take a study treatment and have regular checks by a caregiver and study team.
This study looks at the bacteria in the mouth (periodontal microbiota) to see whether they differ between seniors with Alzheimer’s disease and seniors without it. You may be asked for a sample from your gums/teeth and background health information.
This study tests an experimental drug called LY3439539 in people with early-stage Alzheimer's disease. The drug is designed to target protein changes in the brain that may slow memory loss and cognitive decline.
This trial tests a new drug called CM383 in people with mild cognitive impairment or mild Alzheimer's disease. The goal is to see if it can help slow down memory loss.
This study tests an investigational drug called BEY2153 for people with early Alzheimer's disease (mild cognitive impairment or mild dementia). The goal is to see if it is safe and slows down memory decline.
This study tests a new drug (BnH-015B) for people with moderate Alzheimer's disease. It also includes a small group of healthy young men for comparison. The goal is to see if the drug is safe and how it works in the body.
Hear when a new Alzheimer Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.